口服降糖药钠葡萄糖协同转运蛋白2抑制剂的研究进展

被引：15

作者：

吕秋菊

钟怡

张晋

刘欢

许丹

机构：

[1] 乐山市人民医院

来源：

华西药学杂志 | 2017年 / 32卷 / 03期

关键词：

糖尿病; 钠葡萄糖协同转运蛋白2抑制剂; 达格列净; 卡格列净; 伊格列净; 依帕列净; 空腹血糖; 糖化血红蛋白;

D O I：

10.13375/j.cnki.wcjps.2017.03.034

中图分类号：

R977.15 [];

学科分类号：

摘要：

新型口服降糖药钠葡萄糖协同转运蛋白2（SGLT2）抑制剂达格列净、卡格列净、伊格列净、依帕列净等发挥降血糖作用主要依赖抑制肾小管重吸收葡萄糖,不依赖于胰岛素的作用。临床试验发现:SGLT2抑制剂无论单用还是与传统降糖药合用,都能明显降低2型糖尿病患者的空腹血糖,糖化血红蛋白(HbA1C),兼具降低体重和血压的作用。不良反应方面,SGLT2抑制剂并不会增加低血糖、乳腺癌、膀胱癌和心血管事件等风险,但尿路感染、生殖器感染与低血压的发生率可能增加。

引用

页码：326 / 329

页数：4

共 26 条

[1]

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial [J].

Bailey, C. J. ;

Villegas, E. C. Morales ;

Woo, V. ;

Tang, W. ;

Ptaszynska, A. ;

List, J. F. .

DIABETIC MEDICINE, 2015, 32 (04) :531-541

[2]

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study [J].

Kashiwagi, A. ;

Kazuta, K. ;

Goto, K. ;

Yoshida, S. ;

Ueyama, E. ;

Utsuno, A. .

DIABETES OBESITY & METABOLISM, 2015, 17 (03) :304-308

[3]

Canaglif lozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study [J].

Leiter, Lawrence A. ;

Yoon, Kun-Ho ;

Arias, Pablo ;

Langslet, Gisle ;

Xie, John ;

Balis, Dainius A. ;

Millington, Dawn ;

Vercruysse, Frank ;

Canovatchel, William ;

Meininger, Gary .

DIABETES CARE, 2015, 38 (03) :355-364

[4]

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin [J].

Rosenstock, Julio ;

Hansen, Lars ;

Zee, Pamela ;

Li, Yan ;

Cook, William ;

Hirshberg, Boaz ;

Iqbal, Nayyar .

DIABETES CARE, 2015, 38 (03) :376-383

[5]

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study [J].

Henry, Robert R. ;

Rosenstock, Julio ;

Edelman, Steven ;

Mudaliar, Sunder ;

Chalamandaris, Alexandros-Georgios ;

Kasichayanula, Sreeneeranj ;

Bogle, Allyson ;

Iqbal, Nayyar ;

List, James ;

Griffen, Steven C. .

DIABETES CARE, 2015, 38 (03) :412-419

[6]

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy [J].

Rosenstock, Julio ;

Cefalu, William T. ;

Lapuerta, Pablo ;

Zambrowicz, Brian ;

Ogbaa, Ike ;

Banks, Phillip ;

Sands, Arthur .

DIABETES CARE, 2015, 38 (03) :431-438

[7]

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

de Zeeuw, Dick ;

Mahaffey, Kenneth W. ;

Fulcher, Greg ;

Ways, Kirk ;

Desai, Mehul ;

Shaw, Wayne ;

Capuano, George ;

Alba, Maria ;

Jiang, Joel ;

Vercruysse, Frank ;

Meininger, Gary ;

Matthews, David .

DIABETES CARE, 2015, 38 (03) :403-411

[8]

A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study [J].

Kashiwagi, A. ;

Takahashi, H. ;

Ishikawa, H. ;

Yoshida, S. ;

Kazuta, K. ;

Utsuno, A. ;

Ueyama, E. .

DIABETES OBESITY & METABOLISM, 2015, 17 (02) :152-160

[9]

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea [J].

Ji, L. ;

Han, P. ;

Liu, Y. ;

Yang, G. ;

Van, N. K. Dieu ;

Vijapurkar, U. ;

Qiu, R. ;

Meininger, G. .

DIABETES OBESITY & METABOLISM, 2015, 17 (01) :23-31

[10]

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin<link href="#dom12327-note-0001"/>.[J].M. A. Nauck;S. Del Prato;S. Durán‐García;K. Rohwedder;A. M. Langkilde;J. Sugg;S. J. Parikh.Diabetes Obes Metab.2014, 11

← 1 2 3 →